Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.63 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.63 |
| ▸ | MAPK12 | P53778 | 9/20 | 0.63 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.63 |
| ▸ | RAF1 | P04049 | 7/20 | 0.63 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.63 |
| ▸ | GCGR | P47871 | 2/20 | 0.58 |
| ▸ | CSNK1D | P48730 | 4/20 | 0.49 |
| ▸ | CSNK1E | P49674 | 4/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.46 |
| ▸ | TEK | Q02763 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4488711 | 0.83 | MAPK13 (0.68) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL4490151 | 0.80 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL30365700 | 0.78 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL17002312 | 0.78 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL6451348 | 0.77 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL6929028 | 0.76 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL4463584 | 0.76 | ALOX5 (0.62) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL6470676 | 0.75 | MAPK14 (0.81) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL4478218 | 0.75 | ALOX5 (0.61) | MAPK14MAPK13MAPK12MAPK11RAF1 | |
| SCHEMBL6929830 | 0.74 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670780-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-12-17 | — | — | EP | claimed |
| EP-1670780-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-06-21 | — | — | EP | claimed |
| US-20050209285-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-09-22 | — | — | US | claimed |
| WO-2005030151-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (US) | 2005-04-07 | — | — | WO | claimed |
| US-20090258910-A1 | benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; | IRM LLC (BM) | 2009-10-15 | — | — | US | disclosed |
| US-20090258910-A1 | benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; | IRM LLC (BM) | 2009-10-15 | — | — | US | disclosed |
| US-20090258910-A1 | benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; | IRM LLC (BM) | 2009-10-15 | — | — | US | disclosed |
| US-7569593-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-08-04 | — | — | US | disclosed |
| US-7569593-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-08-04 | — | — | US | disclosed |
| US-7569593-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-08-04 | — | — | US | disclosed |
| US-20050209285-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258910-A1 | benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; | PDGFRA, RAF1, FLT1 | MAPK14 129/4885MAPK13 28/4885MAPK12 67/4885 |
| US-20050209285-A1 | Compounds and compositions as protein kinase inhibitors | LCK, RAF1, MAP3K1 | MAPK14 68/4885MAPK13 80/4885MAPK12 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.